EGFR and neoplasm: Because sorafenib is an inhibitor of the epidermal growth factor receptor (EGFR) that is highly expressed in the tumor tissue as well as in normal tissues, especially in the base layer of the epidermis,19 the expression of EGFR and dose-dependent toxicity at least partly explain the association of skin toxicity with treatment outcomes.